

## CURRICULUM VITAE

**David L. DeRemer, Pharm.D, BCOP, FCCP, FHOPA**

July 2021

---

### **GENERAL INFORMATION**

Office Address: University of Florida College of Pharmacy  
Department of Pharmacotherapy and Translational Research  
HPNP 3308  
Gainesville, FL 32610

Email: [dderemer@cop.ufl.edu](mailto:dderemer@cop.ufl.edu)

Telephone: Office: 352-294-8891  
Fax: 352-273-6485

Present Position(s): Clinical Associate Professor  
Assistant Director of Experimental Therapeutics and Incubator (ETI)  
University of Florida College of Pharmacy  
University of Florida Health Cancer Center

### **EDUCATION**

1992-1996 B.S., Biology  
University of Kentucky College of Arts and Sciences

1998-2002 Doctor of Pharmacy  
University of Kentucky College of Pharmacy

### **POSTDOCTORAL TRAINING**

2002-2003 Pharmacy Practice Residency (ASHP-Accredited)  
University of Kentucky Chandler Medical Center  
Director: Kelly Smith Pharm.D., BCPS, FASHP, FCCP

2003-2004 Hematology-Oncology Residency (ASHP-Accredited)  
University of Kentucky Chandler Medical Center  
Director: Val Adams Pharm.D., BCOP, FCCP, FHOPA

2004-2005 Oncology Postdoctoral Fellowship  
Drug Discovery/Development  
University of Kentucky Chandler Medical Center  
Director: Val Adams Pharm.D., BCOP, FCCP, FHOPA

**ACADEMIC RANK AND APPOINTMENTS**

9/2006-6/2012	Clinical Assistant Professor University of Georgia College of Pharmacy Department of Clinical and Administrative Pharmacy Clinical and Experimental Therapeutics (CET) Program Augusta, GA
7/2012- 8/2017	Clinical Associate Professor University of Georgia College of Pharmacy
7/2013- 8/2017	Adjunct Clinical Associate Professor Medical College of Georgia Department of Medicine, Section of Hematology/Oncology Augusta, GA
9/2017- present	Clinical Associate Professor University of Florida College of Pharmacy Department of Pharmacotherapy and Translational Research

**PROFESSIONAL LICENSURE AND BOARD CERTIFICATION**

2002- current	Kentucky Pharmacy Licensure (#012403)
2005- current	Georgia Pharmacy Licensure (#022799)
2019 – current	Florida Pharmacy Licensure (PS59376)
2006- current	Board of Pharmaceutical Specialties Board Certified Oncology Pharmacist (#506006838) Recertified by CE (2013) Recertified by CE (2020)

**PROFESSIONAL EXPERIENCE**

1996-1998	Senior Lab Technician University of Kentucky College of Medicine Department of Microbiology & Immunology Jesse Siskin, Ph.D. Laboratory
1999-2002	CVS Pharmacy Intern Lexington, KY

2004-2005 Hematology/Oncology PRN Pharmacist  
University of Kentucky Markey Cancer Center  
Lexington, KY

2005-2006 Hematology/Oncology Clinical Specialist  
Bone Marrow Transplant/Oncology Clinical Specialist  
Medical College of Georgia (MCG Inc.)  
Augusta, GA

2006- 2013 Inpatient Hematology/Oncology Clinical Specialist  
Inpatient Bone Marrow Transplant/Oncology Clinical Specialist  
Georgia Regents University Medical Center  
(Formerly Georgia Health Sciences University and MCG Health)  
Augusta, GA

2013- 2017 Outpatient BMT/Hematological Malignancies Clinical Specialist  
Georgia Cancer Center  
Augusta, GA

2017- present Assistant Director of the Experimental Therapeutics Incubator  
University of Florida Health Cancer Center (UFHCC)  
Gainesville, FL

**CERTIFICATIONS/OTHER TRAINING**

2018 NIH – Principles of Clinical Pharmacology Certificate

2015 Chairs and Academic Administrators Management Program (CAAMP)  
Academy for Academic Leadership  
Atlanta, GA

2014 ACCP Focused Investigator Training (FIT) Program  
Athens, GA

2012 CITI- Collaborative IRB Training Initiative Certification  
Georgia Health Sciences University  
Refresher Course Completed (2006, 2009)

2012 CITI Certification for Institutional Review Board Members  
Georgia Health Sciences University

2007	Biosafety Training Certification Medical College of Georgia
2006	Saf-T-Pak Inc Biological Specimens Certification Recertification (2015- Safe Transports of Biological Substances) Medical College of Georgia
2004	Scholarship of Teaching and Learning Certificate Program University of Kentucky Chandler Medical Center
2003	Navigating the Clinical Research Process Investigator Training University of Kentucky Chandler Medical Center
2003	Advanced Cardiac Life Support Certification University of Kentucky Chandler Medical Center
2002	Adult Immunizations Certification University of Kentucky College of Pharmacy

#### **PEER-REVIEWED PUBLICATIONS**

1. Sisken J, **DeRemer DL**. Power frequency electromagnetic fields and the capacitative calcium entry system in SV40-transformed Swiss 3T3 cells. *Radiation Research* 2000;153:699.
2. Ustun C, Farrow S, El-Geneidy, **DeRemer D**, Jillella A. A serious complication of allogeneic stem cell transplantation: Relapsing Pseudomonas aeruginosa panniculitis. *Clinical Medicine: Oncology* 2007: | 91-94
3. Ustun C, Farrow S, **DeRemer D**, Fain H, Jillella A. Early fatal Rhizopus infection on voriconazole prophylaxis following allogeneic stem cell transplantation. *Bone Marrow Transplant* 2007 Jun; 39(12):807-8.
4. Ustun C, **DeRemer DL**, Steele J, Forseen C, Fisher JF, Jillella AP. Fatal breakthrough Aspergillus fumigatus and Candida glabrata infections in a leukemia patient on posaconazole prophylaxis. *Int J Antimicrob Agents*. 2008 Oct; 32(4):365-6.
5. Ustun C, Kalla A, Farrow S, **DeRemer DL**, Jillella A. Decitabine as “bridge therapy” to a MUD transplant in relapsed AML postautologous stem cell transplantation. *Am J Hematol*. 2008 Oct; 83(10):825-7
6. **DeRemer DL**, Natarajan K, Ustun C. Nilotinib (Tasigna®): A second generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

*Clin Ther.* 2008 Nov;30(11):1956-75.

7. Ustun C, **DeRemer DL**, Jillella A, Bhalla KN. Investigational drugs targeting FLT3 for leukemia. *Expert Opinion Investig Drugs* 2009 Oct;18(10):1445-56.
8. Adams VR, **DeRemer DL**, Stevich B, Mattingly C, Gallt B, Subramanian T, Troutman HM, Speilmann HP. Anticancer activity of novel unnatural synthetic isoprenoids. *Anticancer Res.* 2010 Jul;30(7):2505-12.
9. Lewis G, Hall P, Eisa N, **DeRemer DL**, Dobbins R, El-Geneidy M, Jillella A, Ustun C. Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high dose cytarabine consolidations and thus do not require prophylaxis. *Acta Haematologica* 2010 Nov 12;124(4):206-213
10. Ustun C, Jillella A, Shah R, Sterling K, **DeRemer DL**, et al. Second allogeneic stem cell transplantation from different donor improves severe steroid-resistant gut GVHD. *Bone Marrow Transplant* 2010 Nov;45(11):1658-60
11. Willis LM, Somanath PR, El-Remessy AB, **DeRemer DL**, Fagan SC. Angiotensin receptor blockers and angiogenesis: Clinical and experimental evidence. *Clin Science* 2011 Apr; 120 (8):307-19
12. **DeRemer DL**, Katsanevas K, Ustun C. Critical appraisal of nilotinib in the front-line treatment of chronic myeloid leukemia. *Cancer Manag and Res.* 2011 Mar 10;3:65-78.
13. Ustun C, **DeRemer DL**, Akin C. Tyrosine inhibitors in the treatment of systemic mastocytosis. *Leukemia Res.* 2011 Sep;35(9):1143-52
14. Hammadani M, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, Watkins K, Morrison, D, Speir E, **DeRemer D**, Kota V, Jillella A, Craig M, Awan F. Intermediate –versus low dose cyclophosphamide and granulocyte colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma patients treated with novel induction therapies. *Biol Blood Marrow Transplant.* 2012 Jul;18(7):1128-35
15. Awan F, Kochuparambil ST, **DeRemer D**, et al. Plerixafor salvage is safe and effective in hard-to-mobilize patients undergoing chemotherapy and filgrastim-based peripheral blood progenitor cell mobilization. *J Oncol* 2012;2012: 931071
16. Al-Husein B, Abdalla M, Trepte M, **DeRemer DL**, Somanath PR. Anti-angiogenic therapy for cancer: An update. *Pharmacotherapy.* 2012 Dec;32(12):1095-111.
17. **DeRemer DL**, Katsanevas K, Bradley A, Awan F. Romiplostim resistance in secondary failure of platelet recovery (SFPR). *J Oncol Pharm Pract* 2013 Dec;19(4):369-72

18. Bradley A, Devine M, **DeRemer DL**. Brentuximab vedotin: A novel antibody-drug conjugate. *Am J Health Syst Pharm*. 2013 Apr 1;70(7):589-97
19. Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, **DeRemer D**, Jillella A, Craig M, Hamadani M. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. *Bone Marrow Transplant* 2013 Oct;48(10):1279-84
20. Goc A, Al-Husein B, Katsanevas K, Steinbach A, Lou U, Sabbineni H, **DeRemer DL**, Somanath PR. Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression *in vitro* and *in vivo*. *Oncotarget* 2014 15;5(3):775-87.
21. Bradley A, Evans S, **DeRemer DL**, Awan F. Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter? *J Oncol Pharm Pract*. 2015 Dec;21(6):425-32.
22. Clark SM, Clemmons A, Schaack L, Garren J, **DeRemer DL**, Vota V. Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant. *J Oncol Pharm Pract*. 2016 Jun;22(3):416-22.
23. Hartranft M, Clemmons A, **DeRemer DL**, Kota V. Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients. *J Oncol Pharm Pract*. *J Oncol Pharm Pract*. 2017 Jan;23(1):10-17
24. **DeRemer DL**, Clemmons AB, Orr J, Clark SM, Gandhi A. Emerging role of olanzapine for prevention and treatment of chemotherapy-induced nausea and vomiting. *Pharmacotherapy*. 2016 Feb;36(2):218-29.
25. Mangonkar A, Xu H, Moshin J, Mansour J, Chintalapally R, Keen R, Mondal AK, **DeRemer D**, et al. Prognostic value of complete remission with superior platelet counts in acute myeloid leukemia. *J Community Support Oncol*. 2016 Feb;14(2):66-71.
26. Evans SS, Gandhi AS, Clemmons AB, **DeRemer DL**. Clinical and cost comparison evaluation of inpatient versus outpatient administration of EPOCH-Containing regimens in Non-Hodgkin lymphoma. *J Pharm Pract*. 2016 Jul 18. pii: 0897190016659210. [Epub ahead of print]
27. Deal EN, Stranges PM, Maxwell WD, Bacci J, Ashjian EJ, **DeRemer DL**, et al. The importance of research and scholarly activity in pharmacy training. *Pharmacotherapy*. 2016 Dec;36(12):e200-e205.

28. Andrick B, Alwahibi A, **DeRemer DL**, Quershi S, Khan R, Bryan L, Somanath PR, Pantin J. Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukemia patients receiving ibrutinib. *Br J Haematol*. 2018 Sep;182(5):712-714
29. Gwynn ME, **DeRemer DL**. The emerging role of PD-1/PD-L1 targeting immunotherapy in the treatment of metastatic urothelial carcinoma. *Ann Pharmacother*. 2018 Jan;52(1):60-68.
30. Clemmons, AB, Orr, J, Andrick, B, Gandhi, A, Sportes, C, and **DeRemer, DL**. Randomized placebo controlled trial of FOND (fosaprepitant, ondansetron, dexamethasone) versus FOND+O (FOND plus olanzapine) for the prevention of chemotherapy induced nausea and vomiting in hematology patients receiving highly emetogenic chemotherapy regimens: the FOND-O Trial. *Biology of blood and marrow transplantation*. *Biol Blood Marrow Transplant*. 2018 Oct;24(10):2065-2071.
31. Glode AE, Holle L, Nubla J, Minjock M, Egerton N, LeFebvre K, Reff M, **DeRemer D** Collaboration leads to oral chemotherapy education. *J Adv Pract Oncol* 2018;9(7):755–756.
32. Phillips BB, Newsome AS, Bland CM, Palmer R, Smith K, **DeRemer DL**, Phan SV. Evaluation of a pharmacy capstone course to develop patient evaluation skills utilizing the Pharmacists' Patient Care Process. *Am J Pharm Educ*. 2019 Oct;83(8):7357
33. Gwynn ME, **DeRemer DL**, Saunders KM, Parkh J, Bollag R, Clemmons AB. Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors. *J Oncol Pharm Pract*. 2020 Apr;26(3):647-654
34. Marrero RJ, Cicali EJ, Arwood MJ, Eddy E, **DeRemer D**, Ramnarain BH, Daily KC, Jones D Jr, Cavallari LH, Wiisanen KW, Langaee T, Newsom KJ, Starostik P, Clare-Salzer MJ, Johnson JA, George TJ, Cooper-DeHoff RM (in press). How to Transition from Single Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial. *Clin Pharmacol Ther*. 2020 Sept;108(3):557-565
35. Ramnarain BH, Chatzkel JA, Al-Mansour ZA, Rogers S, Jones D, **DeRemer D**, George TJ. Immunotherapy management in special cancer populations. *JCO Oncology Pract*. 2021 Mar 12:OP2000996. doi: 10.1200/OP.20.00996. Online ahead of print.
36. Waheed N, Fradley MG, **DeRemer D**, Mahmoud A, Shah CP, Langaee TY, Lipori GP, March K, Pepine CJ, Cooper-DeHoff RM, Wu Y, Gong Y. Newly diagnosed cardiovascular disease in patients treated with Immune Checkpoint Inhibitors: A retrospective analysis of patients at an academic tertiary care center. *Cardiooncology*. 2021 Mar 18;7(1):10. doi: 10.1186/s40959-021-00097-9.
37. Tantawy M, Chekka LM, Huang Y, Garrett TJ, Singh S, Shah CP, Cornell RF, Baz RC, Fradley MG, Waheed N, **DeRemer DL**, Yan L, Langaee T, March K, Pepine CJ, Moreb JS, Gong Y. Lactate dehydrogenase B and pyruvate oxidation pathway associated with carfilzomib-Related

cardiotoxicity in multiple myeloma patients: Result of a Multi-omics integrative analysis. *Front. Cardiovas Med* 29 Apr 2021 <https://doi.org/10.3389/fcvm.2021.645122>

38. Chen Z, Cheng Y, **DeRemer DL**, Diaby V. Cost-effectiveness and Drug Wastage of Immunotherapeutic Agents for Hematologic Malignancies: A Systematic Review. *Expert Rev Pharmacoecon & Outcomes Res.* 2021 May 2:1-19. doi: 10.1080/14737167.2021.1913056. Online ahead of print.
39. TG George, Ali A, Wang Y, Lee JH, Ivey A, **DeRemer D**, et al. Phase II Study of 5-fluorouracil, oxaliplatin plus dasatinib (FOLFOX-D) in first-line metastatic pancreatic adenocarcinoma. *The Oncologist* 2021 Jun 8. doi: 10.1002/onco.13853. Online ahead of print.

### **NON-PEERED REVIEWED**

1. Adams VR, **DeRemer, DL**, Kilbridge JF. Apoptosis: Novel Molecular Targets in Cancer Therapy, Clinical Focus on Bcl-2. *Oncology Special Edition* Dec 2004.
2. **DeRemer DL**. Blincyto® (blinatumomab) for patients with Philadelphia chromosome-negative relapsed or refractory B-Cell precursor acute lymphoblastic leukemia. *Pharmacy Practice News* March 2015.
3. **DeRemer DL**. Empowering Community Pharmacists as Health Consultants: Chemotherapy-Induced Nausea and Vomiting. *Inside Patient Care*. December 2015.
4. **DeRemer DL**. Board Update: The Common Denominator. *HOPA News*. Vol 17; 2, 2020.
5. **DeRemer DL**. Board Update: Accelerating to the Next Chapter. *HOPA News*. Vol 17; 3, 2020.
6. Pan K, Skelton WP, **DeRemer DL**, George TG. In Hot Pursuit of RAS Inhibition. *ASCO Daily News*, January 3, 2020.
7. **DeRemer DL**. Board Update: Anticipating the Green Lights Ahead. *HOPA News*. Vol 17; 4. 2021.
8. **DeRemer DL**. Board Update: Spring Forward. *HOPA News*. Vol 18; 1. 2021.

### **BOOK CHAPTERS**

1. Gerson SL, Bhalla KN, Grant S, Natarajan K, Grant S, Creger RJ, **DeRemer D**. *Pharmacology and Molecular Mechanisms of Antineoplastics Agents for Hematologic Malignancies*. In: *Hematology: Basic Principles and Practice* (eds Hoffman R, Silberstein LE, Shattil SJ, et al.) 5th edition. Elsevier, Philadelphia, PA. 2008, p 839-873.
2. **DeRemer DL** *Leukemias*. In: Sutton NAPLEX Review Guide. 1st edition. McGraw-Hill., New York. 2011 p143 -150.



3. **DeRemer DL**, Manasco KB, Fagan SC. *Research: Becoming a Scholar*. In: Murphy JE (ed) American College of Clinical Pharmacy Resident Survival Guide. Lenexa, KS, 2011.
4. **DeRemer DL**. Drug and Food Interactions with Tyrosine Kinase Inhibitors. In: Ustun C and Popat UR (eds): *Chronic Myeloid Leukemia: From Daily Management to Complicated Issues*. New York, NY: Nova Science Publishers; 2014 pp. 251-262.
5. **DeRemer DL** *Leukemias*. In: Sutton NAPLEX Review Guide. 2nd edition. McGraw-Hill., New York. 2015.
6. **DeRemer DL** *Leukemias*. In: Sutton NAPLEX Review Guide. 3rd edition. McGraw-Hill., New York. 2018.
7. **DeRemer D**, Higgins T. Acute Leukemias. In: DiPiro JT, Yee GC, Posey L, Haines ST, Nolin TD, Ellingrod V. eds. *Pharmacotherapy: A Pathophysiologic Approach, 11e* New York, NY: McGraw-Hill Companies, Inc: New York, 2020.

#### **SECTION EDITOR**

1. **DeRemer DL** (*section ed*) Barnett C, Malara J, Kimmel J. Breast Cancer. In: O'Connell M, Smith JA. eds. *Women's Health Across the Lifespan, 2e* New York, NY: McGraw-Hill; 2019.
2. **DeRemer DL** (*section ed*) Mach CM, Hall TR. Endometrial Cancer. In: O'Connell M, Smith JA. eds. *Women's Health Across the Lifespan, 2e* New York, NY: McGraw-Hill; 2019.
3. **DeRemer DL** (*section ed*) Crane EK. Ovarian Cancer. In: O'Connell M, Smith JA. eds. *Women's Health Across the Lifespan, 2e* New York, NY: McGraw-Hill; 2019.
4. **DeRemer DL** (*section ed*) Berman T, Smith JA. Cervical Cancer. In: O'Connell M, Smith JA. eds. *Women's Health Across the Lifespan, 2e* New York, NY: McGraw-Hill; 2019.
5. **DeRemer DL** (*section ed*) Saadeh C, Ottney A. Management of Treatment Complications. In: O'Connell M, Smith JA. eds. *Women's Health Across the Lifespan, 2e* New York, NY: McGraw-Hill; 2019,

#### **HANDBOOKS**

1. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. *Guide to Cancer Chemotherapeutic Regimens*. McMahan Publishing, New York, NY 2004
2. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. *Guide to Cancer Chemotherapeutic Regimens*. McMahan Publishing, New York, NY 2005

3. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2007
4. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2008
5. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2009
6. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2010
7. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2011
8. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2012
9. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2013
10. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2014
11. Adams, V.R. **DeRemer DL**, Bernhardt, MB. Guide to Cancer Therapeutic Regimens. McMahon Publishing, New York, NY 2017.

### **ABSTRACTS/POSTERS**

1. Liewer SE, Hecht KA, Smith, CA, **DeRemer DL**, Adams VR, et al. Gelclair® for the treatment chemotherapy induced stomatitis in transplant and hematology patients: An interim analysis. Blood. 2004 Nov 16;104: 5317
2. Gallt RR, Mattingly CA, **DeRemer DL**, Adams VR. Determination of in vitro growth inhibition by novel farnesyl diphosphate analogues. American College of Clinical Pharmacy (ACCP) Annual Meeting 2005 San Francisco, CA. Abstract #511
3. **DeRemer DL**, Mattingly CA, Adams VR. In vitro interaction between topotecan (TPT) and paclitaxel (PAC) in three human ovarian cancer cell lines. ACCP Annual Meeting 2005 San Francisco, CA. Abstract #245

4. Kendrick A, Lake B, **DeRemer D**, Fain H, Farrow S, Ustun C, and Jillella A. Analysis of febrile neutropenia in multiple myeloma patients post-autologous hematopoietic stem cell transplantation (HSCT). Presented at the 2007 American Colleges of Clinical Pharmacy Annual Meeting Denver, CO; October 15, 2007. Abstract #353.
5. Kendrick A, **DeRemer DL**. Evaluation of institutional BMT program compliance with recommended post-hematopoietic stem cell transplant (HSCT) vaccination guidelines. Presented at 2007 American Health System Pharmacy (ASHP) Annual Meeting Las Vegas, NV; December 2007
6. Fussell J, Boyle K, Kuth J, **DeRemer DL**, Ustun C. Review of institutional use of prophylactic voriconazole and posaconazole in patients with hematological malignancies. Presented at 2007 American Health System Pharmacy (ASHP) Annual Meeting Las Vegas, NV; December 2007.
7. Stevich B, Mattingly C, **DeRemer DL**, Spielmann P, Adams V. Targeting Ras with false prenyl analogs. Presented at 2008 American Colleges of Clinical Pharmacy (ACCP) Annual Meeting Louisville, KY; October 2008.
8. Carbonell C, **DeRemer DL**. Institutional analysis of rasburicase in the management of tumor lysis syndrome. Presented at 2008 American Health System Pharmacy (ASHP) Annual Meeting Orlando, FL. December 2008.
9. Nestor MA, **DeRemer DL**. Evaluation of outcomes in acute promyelocytic leukemia patients receiving ATRA (All-trans Retinoic Acid). Presented at 2008 American Health System Pharmacy (ASHP) Annual Meeting Orlando, FL. December 2008
10. Almeter PJ, Robinson T, **DeRemer DL**. Institutional evaluation of vancomycin in neutropenic patients. Presented at 2008 American Health System Pharmacy (ASHP) Annual Meeting Orlando, FL. December 2008.
11. Maciuleviciute E, Davis W, **DeRemer DL**. Evaluation of hypertension management bevacizumab treated patients. Presented at the 2008 University Health Consortium Pharmacy Council Resident Poster Session, Orlando, FL. December 6, 2008
12. Graham CR, Butterfield J, **DeRemer DL**. Impact of peptide nucleic acid fluorescence in situ hybridization (PNA FISH)-based identification of Candida species on antifungal utilization. Presented at the 2009 University Health Consortium Pharmacy Council Resident Poster Session, Las Vegas, NV. December 5, 2009
13. Mebel E, McAllister J, **DeRemer DL**. Evaluation of plerixafor on stem cell collection prior to an autologous hematopoietic stem cell transplant (aHSCT). Presented at 2009 American Health System Pharmacy (ASHP) Annual Meeting Las Vegas, NV. December 2009.

14. Awan F, **DeRemer D**, Mebel E, et al. Utility of plerixafor in addition to chemotherapy and G-CSF mobilization regimens. *Blood (American Society of Hematology (ASH) Annual Meeting)* 2010;116: 4443.
15. Katsanevas K, Ajiboye V, **DeRemer DL**. Evaluation of pegfilgrastim for primary prophylaxis for of neutropenic fever. Presented at the 2010 University Health Consortium Pharmacy Council Resident Poster Session, Anaheim, CA. December 4, 2010
16. Kochuparambil T, **DeRemer DL**, Mebel ER, Jillella AP, Awan F. Optimizing the efficacy of plerixafor as a salvage option in poor mobilizers following chemotherapy plus G-CSF. Presented at the 2011 American Society for Blood and Marrow Transplantation (ASBMT) Meeting. Honolulu, HI. February 17-21, 2011
17. Stoudenmire LL, Trepte M, McCracken C, Katsanevas K, **DeRemer DL**. Evaluation of obesity on achieving remission following induction therapy for acute myelogenous leukemia. ACCP Annual Meeting 2011 Pittsburgh, PA. Abstract # 448
18. Morrison DD, Kochuparambil ST, **DeRemer DL**, et al. Clinical Practice Guideline for the treatment of BK-Virus induced Hemorrhagic Cystitis in the Post-Allogeneic Hematopoietic Stem Cell Transplant Setting. Volume 18 Issue 2. Presented at the American Society of Bone Marrow Transplant (ASBMT) Annual Meeting at San Diego, CA. Feb 1-5, 2012.
19. Hamadani S, Kochuparambil ST, Osman S, Speir E, Craig M, **DeRemer D**, et al. Intermediate-versus low-dose cyclophosphamide and granulocyte colony stimulating factor for peripheral blood progenitor cell mobilization in patients with multiple myeloma treated with novel induction chemotherapies – A multicenter analysis. *Blood (ASH Annual Meeting Abstracts)*, Nov 2011;118: 313.
20. Katsanevas K, Al-Husein B, **DeRemer D**, Shenoy S. Is GSK-3 the gridlock in Akt-targeted prostate cancer therapy? Presented at the 2012 Hematology/Oncology Pharmacist Association (HOPA) Meeting, Orlando, FL. March 22, 2012.
21. **DeRemer DL**, Katsanevas K, Forehand C, et al. Successfully integrating translational research into a PGY2 research project. Presented at the 2012 ASHP National Residency Preceptors Conference in Washington, DC. August 17, 2012.
22. **DeRemer DL**, Katsanevas K, Lou U, et al. Src inhibition with dasatinib offers potential benefit for prostate cancer. Presented at the 2012 STAR (Southern Translational Research) Conference in Augusta, GA. September 6, 2012.
23. Evans S, **DeRemer D**, Bradley A. Intravenous busulfan pharmacokinetics in conditioning regimens for allogeneic stem cell transplantation: impact of dosing weight on clinical outcomes.

Presented at the 2012 STAR (Southern Translational Research) Conference in Augusta, GA. September 6, 2012.

24. Awan F, Kochuparambil ST, Craig M, Cumpstom A, Leadmon, S, Watkins K, **DeRemer D**, Pantin J, Kota V, Jillella AP, Hamadani. Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC) Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction Chemotherapies – A Multicenter Analysis. Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 4409
25. Steinbach A, Goc A, **DeRemer D**, Shenoy S. Evaluation of cabazitaxel and dasatinib on the reciprocity between prostate cancer and the endothelium in the prevention of micrometastasis. Presented at the 9<sup>th</sup> Annual HOPA Conference in Los Angeles, GA. March 21, 2013.
26. Schaack L, Clark SM, Clemmons AB, **DeRemer DL**, Kota V. Characterization of chemotherapy induced nausea and vomiting outcomes in patients receiving melphalan-containing conditioning chemotherapy for autologous hematopoietic stem cell transplant. Presented at 2013 ACCP Annual Meeting in Albuquerque, NM. Abs #347
27. Clark SM, Schaack L, **DeRemer D**, Kota V, Clemmons AB. Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan conditioning regimens for autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Feb;20(2 Suppl):S287.
28. Hartranft ME, **DeRemer DL**, Kolhe R, Phillips BG. Investigation of epigenetic modifications in obese and non-obese acute myeloid leukemia patients. Presented at 10<sup>th</sup> Annual Meeting of the Hematology/Oncology Pharmacy Association (HOPA), New Orleans, LA. Resident Trainee Poster #125
29. **DeRemer DL**, Hartranft ME, Mondal A, Kolhe R, Meagher R, Phillips BG. Evaluation of the effects of obesity on the epigenome in acute myeloid leukemia patients: Correlation with clinical outcome and drug response. Presented at 2014 ACCP Annual Meeting in Austin, TX. Abs#442.
30. Evans S, Clemmons AB, Gandhi A, **DeRemer D**. Clinical and economic evaluation of inpatient versus outpatient administration of EPOCH-containing regimens in Non-Hodgkin lymphoma. Presented at 12th Annual Meeting of the Hematology/Oncology Pharmacy Association (HOPA), Austin, TX. Resident Trainee Poster #32
31. Orr J, Clemmons AB, Gandhi A, **DeRemer D**. Randomized, placebo-controlled study of FOND (fosaprepitant, ondansetron, dexamethasone) versus FOND+O (FOND plus olanzapine) for the prevention of CINV in hematology patients receiving highly emetogenic chemotherapy regimens (The FOND-O Study). Presented at 12th Annual Meeting of the Hematology/Oncology Pharmacy Association (HOPA), Atlanta, GA. Resident Trainee Poster #100

32. Andrick B, **DeRemer D**, Abdul Sater- H, Bollag R, Pantin J, Shenoy S. Pneumococcal vaccine response in chronic lymphocytic leukemia patients with ibrutinib. Presented at 12th Annual Meeting of the Hematology/Oncology Pharmacy Association (HOPA), Atlanta, GA. Resident Trainee Poster #27
33. Andrick B, Alwhaibi A, **DeRemer D**, Quershi, Khan R, Shenoy S, Pantin J. Antibody response to pneumococcal conjugate vaccine (PCV13) in chronic lymphocytic leukemia patients receiving ibrutinib. *Blood* 2016 128:5597.
34. George TJ, Starr JS, Parkeh HD, Ivery AM, Dang LH, Daily KC, Allegra CJ, **DeRemer DL**, et al. Final toxicity results from a phase II study of 5-fluorouracil, oxaliplatin and dasatinib (FOLFOX-D) in previously untreated metastatic pancreatic adenocarcinoma. 2018 Gastrointestinal Cancers Symposium ASCO Meeting, abstract #504.
35. Gwynn M, **DeRemer D**, Saunders K, Parikh J, Bollag R, Clemmons AB. Evaluation of immune-mediated adverse events after influenza vaccination in cancer patients receiving immune checkpoint inhibitors. Presented at Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, Denver, CO. Resident Trainee Poster #71
36. George TJ, Starr JS, Parkeh HD, Ivery AM, McGorray SP, Wang Y, Dang LH, Daily KC, Allegra CJ, **DeRemer DL**, et al. Final results from a phase II study of 5-fluorouracil, oxaliplatin, and dasatinib (FOLFOX-D) in previously untreated metastatic pancreatic adenocarcinoma. *J Clin Oncol* 36, 2018 (suppl; abstr 4124)
37. Parekh H, **DeRemer DL**, Hitchcock K, et al. A phase II, open-label pilot study evaluating the safety and activity of nal-IRI in combination with 5-FU and oxaliplatin in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study). *J Clin Oncol* 37, 2019 (suppl 4; abstr TPS476)
38. Quiroga LC, Dyer CS, **DeRemer DL**. Evaluation of immune checkpoint inhibitor response in cancer patients who have received antibiotic therapy. Presented at 2019 ACCP Annual Meeting Poster Session– New York, NY.
39. Lofy M and **DeRemer DL**. Next generation sequencing (NGS) based molecular profiling of head and neck squamous cell carcinoma (HNSCC): Treatment strategies and outcomes. Presented at 2020 HOPA Annual Meeting Poster Session– Tampa, FL.
40. Heiman E and **DeRemer DL**. Next generation sequencing (NGS) based molecular profiling of breast and ovarian cancer patients: Treatment strategies and outcomes. Presented at 2020 HOPA Annual Meeting Poster Session– Tampa, FL.

41. Karimi S and **DeRemer DL**. Next generation sequencing (NGS) based molecular profiling of adult central nervous system (CNS) cancer patients: Treatment strategies and outcomes. Presented at 2020 HOPA Annual Meeting Poster Session– Tampa, FL.
42. Shahidadpury V and **DeRemer DL**. Next generation sequencing (NGS) based molecular profiling of pancreatic cancer patients: Treatment strategies and outcomes. Presented at 2020 HOPA Annual Meeting Poster Session– Tampa, FL.
43. Tantawy M, Chekka L, Huang Y, Garret T, Singh S, Shah CP, Cornell RF, Baz RC, Fradley MG, Waheed N, **DeRemer DL**, et al. Lactate Dehydrogenase B And Pyruvate Oxidation Associated With Carfilzomib-Related Cardiotoxicity In Multiple Myeloma Patients: A Multi-omics Study. Abstract #15012 Accepted for American Heart Association Conference.
44. Nguyen NK, Fradley MG, Chen Y, **DeRemer D**, et al. Racial/Ethnic Differences In Cardiac Surveillance Evaluation For Cancer Patients Treated With Anthracycline-based Chemotherapy: The OneFlorida Clinical Research Consortium. Abstract #16457 Accepted for American Heart Association Conference.
45. Tantawy M, Chekka LM, Garrett TJ, Singh S, Shah CP, Fradley MG, Cornel RF, Baz R, **DeRemer DL**, Yuan L, Langaee T, March K, Pepine CJ, Moreb JS, Gong Y. Lactate Dehydrogenase B and pyruvate oxidation associated with carfilzomib-related cardiotoxicity in multiple myeloma patients: a multi-omics study. *Circulation*. 2020;142: A15012
46. Ramnarain R, Hughes S, Hitchcock K, Lee J-H, Rogers SC, Fan H, Allegra CJ, Trevino J, El-Far A, Russell KB, Turk A, **DeRemer DL**, George TJ. A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study). 2021 ASCO Gastrointestinal Cancers Symposium. Abstract #32200

### **CLINICAL TRIALS**

1. A Phase IA/II, two-arm, multi-center, open-label, dose escalation study of LBH589 administered orally via different dosing schedules in adult patients with advanced hematological malignancies. – Role: Institutional Sub-I. 2006-2008
2. Randomized, placebo-controlled study of FOND (fosaprepitant, ondansetron, dexamethasone) versus FOND+O (FOND plus olanzapine) for the prevention of chemotherapy induced nausea and vomiting in hematology patients receiving highly emetogenic chemotherapy regimens: the FOND-O Study. (NCT02635984)- Investigator Initiated Trial, Role: Institutional Sub-I. 2015-2017
3. An open-label study of rovalpituzumab tesirine in subjects with delta-like protein 3-expressing advanced solid tumors. Role: Institutional Sub-I. 2017-2018

4. A Phase I, open-label study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment. Role: Institutional Sub-I. 2017-2018
5. A Phase 1/2, Open-label study of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic solid tumors (CheckMate 032) Role: Institutional Sub-I. 2017-2018.
6. A Phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 alone and in combination with MEDI4736 in adult subjects with select advanced solid tumors. Role: Institutional Sub-I. 2017-2018.
7. A Phase 1/2 study exploring the safety, tolerability, and efficacy of INCAGN01876 in combination with immune therapies in subjects with advanced or metastatic malignancies. Role: Institutional Sub-I. 2017 –2019.
8. A Phase 1 Study of NLG802 for Adult Patients with Recurrent Advanced Solid Tumors. Role: Institutional Sub-I. 2018-2019.
9. DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (SWOG 1609) Role: Institutional Sub-I. 2017-2020.
10. A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification (ETCTN 10136) Role: Institutional Sub-I. 2019-2020.
11. A Randomized Pragmatic Trial of Genotype-Guided Supportive Care in Symptom Treatment of Cancer Patients (UF-ETG-002) Role: Institutional Sub-I. 2019-2020.
12. Molecular Analysis for Therapy Choice (MATCH) Role: Institutional Sub-I. 2017- current.
13. Open Label Phase 2 Study of tisotumab vedotin for Locally Advanced or Metastatic Disease in Solid Tumors. Institutional Role: Sub-I. 2018-current.
14. Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors (ETCTN 9938). Institutional Role: Sub-I. 2018-current.
15. Phase 1 Dose Escalation and Randomized Phase 2 Trial of Carboplatin and Gemcitabine With or Without VX-970 in First Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer (ETCTN 9948). Institutional Role: Sub-I. 2018-current.



16. A Phase 1 Study of Pembrolizumab (MK-3475) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors. Institutional Role (ETCTN 10161): Role: Institutional Sub-I. 2018-current.
17. Phase II Trial of the PARP1 Inhibitor, Niraparib, in BAP1 and other DNA Damage Response (DDR) Pathway Deficient Neoplasms (UF-STO-ETI-001) Institutional Role: Sub-I. 2018-current
18. A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer Institutional Role: Sub-I. 2018-current
19. A Phase II, Open-label Evaluating the Safety and Activity of nal-IRI in Combination with 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (UF-STO-PANC-004) Institutional Role: Sub-I. 2019-current
20. A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b. Institutional Role: Sub-I. 2019-current
21. A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C (CodeBreak 100) Institutional Role: Sub-I. 2020-current
22. A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors (ETCTN 10129) Institutional Role: Sub-I. 2020-current
23. A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic colorectal Cancer (ETCTN 10181) Institutional Role: Sub-I. 2020-current
24. A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects With Advanced Solid Tumors. Institutional Role: Sub-I. 2021-current

## **PRESENTATIONS**

### **National**

1. *Schedule-dependent Synergism and Antagonism between Paclitaxel and Topotecan in Human Ovarian Cancer Cell Lines in vitro*. Scientific Paper Platform Presentation. Presented at American College of Clinical Pharmacy (ACCP) Annual Meeting; San Francisco, CA. October 2005

2. *Strategies for Success in Pharmacy Board Certification: A Panel Discussion*. Panel – Smith KM, Canada TW, Divine H, Jennings HR. Presented at the 42<sup>nd</sup> American Society of Health Systems Pharmacists (ASHP) Midyear Clinical Meeting; Las Vegas, NV. December 2, 2007
3. *Hodgkin Lymphoma BCOP Recertification Presentation*. Presented at the 9<sup>th</sup> Annual Hematology Oncology Pharmacists Association (HOPA) Annual Meeting; Los Angeles, CA. March 2013.
4. *Trending now #ExcellenceInPrecepting – effective ways to incorporate social media into clinical practice*. Co-presenters- Clark S and Hartranft M. Presented at the ASHP National Pharmacy Preceptors Conference; Washington DC. August 22, 2013.
5. *Have you submitted that paper yet? Successfully precepting student and resident research projects*. Co-presenters- May JR, Phillips BJ, Phillips M. Presented at the ASHP National Pharmacy Preceptors Conference; Washington DC. August 23, 2013.
6. *Hodgkin Lymphoma BCOP Recertification Presentation*. Presented at American College of Clinical Pharmacy (ACCP) Annual Meeting Albuquerque, NM. October 15, 2013.
7. *Hodgkin Lymphoma BCOP Recertification Presentation*. Presented at ASHP Annual Meeting Orlando, FL. December 10, 2013.
8. *Evaluation of the effects of obesity on the epigenome in acute myeloid leukemia patients: Correlation with clinical outcomes and drug response*. The Great Eight Best Paper Presentations Series. Presented at American College of Clinical Pharmacy (ACCP) Annual Meeting Austin, TX. October 13, 2014
9. *Hematology/Oncology PRN Focus Session: Confronting the Global Epidemic of Human Papillomavirus (HPV) and Associated Malignancies*. Moderator at Global American College of Clinical Pharmacy (ACCP) Annual Meeting San Francisco, CA. October 19, 2015.
10. *Recent Advances in the Treatment and Management of Lymphomas*. Presented at HOPA BCOP Updates Course Orlando, FL. July 16, 2016.
11. *Malignancy in the HIV Patient*. Presented at the ACCP Annual Meeting Hollywood, FL. October 24, 2016.
12. *Oral Chemotherapy Education*. Presented at the National Community Oncology Dispensing Association (NCODA) Annual Summit Atlanta, GA. October 29, 2016.
13. *Managing Acute Lymphoblastic Leukemia (ALL): A Review on Diagnosis and Clinical Considerations for the Healthcare Professional*. Webinar provided by Specialty Pharma Education Center, 2016.

14. *Cracking the Code on Oral Chemotherapy: Pharmacotherapy Management and Counseling Strategies*. Presented at the ACCP Annual Meeting Phoenix, AZ. October 10<sup>th</sup>, 2017.
15. *Oral Chemotherapy Education*. Presented at the NCODA Annual Meeting Orlando, FL. October 19, 2017.
16. *Emerging Treatment Options for Relapsed/Refractory Hodgkin Lymphoma*. ASHP Advantage Webinar. October 26, 2017.
17. *Embracing the Mid-Career Crisis: Pivoting to New Career Challenges*. Presented at the HOPA Annual Conference in Denver, CO. March 24, 2018.
18. *Exploring Treatment Options for Patients with Acute Lymphoblastic Leukemia (ALL)*. Pharmacy Times CE Webinar. May 22, 2018.
19. *Oncologic Pharmacology – Alkylating Agents*. ASCO University Webinar. September 2018.
20. *Oncologic Pharmacology – Topoisomerase Inhibitors and Antibiotics*. ASCO University Webinar. September 2018.
21. *Oncologic Pharmacology – Antimicrotubule Agents*. ASCO University Webinar. September 2018.
22. *Updates from the 2018 American Society of Clinical Oncology Meeting – Hematology Focused*. HOPA Emerging Issues in Oncology Webinars. September 27, 2018.
23. *Precision Immunotherapy*. Presented at the ACCP Annual Meeting Seattle, WA. October 20<sup>th</sup>, 2018.
24. *The Value of Treatment Support Kits and Oral Chemotherapy Education Sheets (Moderator)*. NCODA Annual Fall Conference in Orlando, FL. October 26, 2019.
25. *Advances in Cancer Drug Therapy: New Agents and New Strategies*. APP Oncology Summit in Pasadena, CA. February 8, 2020.
26. *Potential for Anticancer agents in the Treatment of COVID19*. Association of Value-Based Cancer Care- Webinar. July 14, 2020.
27. *Changes in Cancer Care: Practicing Pharmacy in the Era of COVID-19*. Keynote Speaker Directions in Oncology Pharmacy Conference Series (Pharmacy Times CE). Chicago, IL (virtual due to COVID-19). September 26, 2020.
28. *Advances in Cancer Drug Therapy: New Agents and New Strategies*. APP Oncology Summit in Nashville, TN (virtual due to COVID-19). September 26, 2020.

29. *Changes in Cancer Care: Practicing Pharmacy in the Era of COVID-19*. Keynote Speaker Directions in Oncology Pharmacy Conference Series (Pharmacy Times CE). Orlando, FL (virtual due to COVID-19). October 10, 2020.
30. *Changes in Cancer Care: Practicing Pharmacy in the Era of COVID-19*. Keynote Speaker Directions in Oncology Pharmacy Conference Series (Pharmacy Times CE). Anaheim, CA (virtual due to COVID-19). October 24, 2020.
31. *Changes in Cancer Care: Practicing Pharmacy in the Era of COVID-19*. Keynote Speaker Directions in Oncology Pharmacy Conference Series (Pharmacy Times CE). New York, NY (virtual due to COVID-19). November 7, 2020.
32. *The Evolution of Drug Therapy in Oncology: Recent Advances in Cancer Drug Therapy*. APP Oncology Summit in Philadelphia, PA (virtual due to COVID-19). May 15, 2021.
33. *COVID-19 Vaccinations: When to Dose?* Co-presenter – James Lewis, Pharm.D. FIDSA, Oregon Health Sciences University; Great Debates and Updates in Oncology Pharmacy series. July 22, 2021.

#### Regional

1. *The Specific Role of 92kDa Type IV Collagenase in Metastatic Tumor Cells* Howard Hughes Research Award Winners Presentation. Kentucky/Tennessee Academy of Science Joint Meeting Bowling Green, KY. May 1996
2. *Erythropoietin Response in Patients Concurrently Receiving Capecitabine* ACPE accredited continuing education program. Southeastern Residency Conference University of Georgia. Athens, GA. May 2003
3. *Thymoquinone: Analytical Method and Assay Validation*. Southeastern Residency Conference. ACPE accredited continuing education program. University of Georgia. Athens, GA. May 2004
4. *Selected Overview of Recently Approved Oncology Agents: Targeting New Molecular Targets* Kentucky Health System Pharmacists (KSHP) Annual Meeting. ACPE accredited continuing education program.. Lexington, KY. September 2004.
5. *New Oncology Agents*. Georgia Health System Pharmacists (GHSP) Fall Annual Meeting ACPE accredited continuing education program. Helen, GA October 2006.
6. *The Generational Joust: Strategies for Boomers and GenXers as the Millennials Enter the Profession of Pharmacy*. Georgia Health System Pharmacists (GHSP) Summer Annual Meeting. ACPE accredited continuing education program. Amelia Island, FL June 2008

7. *Breast and Gynecological Cancers*. South Carolina Pharmacists Association Summer Meeting ACPE accredited continuing education program. Hilton Head, SC June 2010.
8. *Managing Vascular Complications Associated with Novel Targeted Chemotherapy Agents* Georgia Health System Pharmacists (GHSP) Summer Annual Meeting. ACPE accredited continuing education program. Amelia Island, FL July 2012.
9. *Confronting the Rise of Cancers in the HIV Population*. Georgia Health System Pharmacists (GHSP) Summer Annual Meeting. ACPE accredited continuing education program. Amelia Island, FL July 2017.
10. *Mid-Career Crisis and Burnout: Refocus or Transition to New Challenges*. (GHSP) Summer Annual Meeting. ACPE accredited continuing education program. Amelia Island, FL July 2018.
11. *Immuno-oncology Management in Special Populations*. (Moderator) – ASCO Direct Highlights: Therapeutic Immuno-oncology Advances for the Practitioner. October 8, 2020.

#### State/Local

1. *Angiogenesis: Switching On/Off Molecular Targets for Differing Clinical Outcomes* ACPE accredited continuing education program. MCG/UGA Pharmacy Grand Rounds, Augusta, GA. February 2006.
2. *What's "Hot" in the Treatment of Leukemias*. ACPE accredited continuing education program MCG/UGA Pharmacy Grand Rounds, Augusta, GA. October 2006.
3. *Perspective of a New Generation Xer Professor- Challenges and Strategies of Teaching the Millennials*. ACPE accredited continuing education program/ MCG/UGA Pharmacy Grand Rounds, Augusta, GA. October 2007.
4. *Neurotoxicity of Chemotherapeutic Agents*. MCG Neurology Resident Ground Rounds Series Medical College of Georgia, Augusta, GA. February 2008.
5. *Recent Significant Advances in Oncology*. ACPE accredited continuing education program. MCG/UGA Pharmacy Grand Rounds, Augusta, GA. Transmitted video to Savannah and Athens, GA. April 2009.
6. *Making it less MUDdy: Understanding Matched Unrelated Donor Bone Marrow Transplants*. ACPE accredited continuing education program. GHSU/UGA Pharmacy Grand Rounds, Augusta, GA. Transmitted video to Savannah, Athens, and Albany, GA. April 2011

7. *Maintaining the Maintenance: Is this the Future of Cancer Therapy*. ACPE accredited continuing education program. GHSU/UGA Pharmacy Grand Rounds, Augusta, GA. Transmitted video to Savannah, Athens, and Albany, GA. October 2012.
8. *Recent Advances in Cancer Immunotherapy: Developing a Killer Instinct*. ACPE accredited continuing education program. GRU/UGA Pharmacy Grand Rounds, Augusta, GA. Transmitted video to Savannah, Athens, and Albany, GA. September 2014.
9. *Hematopoietic Growth Factors*. Augusta University Division of Hematology/Oncology Fellows Grand Rounds. February 8, 2017.
10. *Immunotherapy*. UF Health Clinical Trials Office (CTO) Grand Rounds. September 21, 2018.
11. *Spotlight on Oncology Pharmacy*. UF Pre-Pharmacy Society. December 3, 2018.
12. *Career Spotlight – Oncology Pharmacy*. UF FSHP Student Meeting. October 14, 2019.
13. *Review of Immune-Mediated Adverse Events (imAEs) in Patients Receiving Immune Checkpoint Inhibitors*. UF Health Cancer Center Immuno-oncology Working Group Meeting. October 22, 2019.
14. *Oncology Pharmacy Practice In the Climate of COVID-19*. Kentucky Hematology/Oncology Pharmacy Symposium. September 18, 2020.
15. *Recent Updates in the Treatment of NSCLC*. UF College of Pharmacy. Tobacco and Alcohol Awareness Committee – Lunch and Learn. October 21, 2020

## **TEACHING ACTIVITY**

### **University of Florida College of Pharmacy**

#### ***Precision Medicine Program***

PHA6136 Clinical Applications of Precision Medicine: Oncology  
2019, 2020 (two semesters): Course coordinator

#### ***Pharm.D. Curriculum***

PHA5933 Oncology Clinical Trial Evaluation (Elective)  
2020: Course Coordinator, lecturer, Active learning facilitator (10 contact hours)

PHA5782 Patient Care II Introduction to Infectious Diseases and Hematology/Oncology  
2018-2020: Lecturer - Immunotherapy, Antiemetic Pharmacology, Antiemetic Therapeutics, NHL, Hodgkin Lymphoma; Active learning facilitator - HL/antiemetics/Immunotherapy (10 contact hours)

PHA5878 Patient Care III Introduction to Cardiovascular and Pulmonary Disease

2018-2020: Lecturer – Lung Cancer (2 contact hours); Active learning facilitator – Lung Cancer

PHA5784C Patient Care IV Gastrointestinal and Renal Disorders

2019-2021: Lecturer – Colorectal Cancer, Colorectal Cancer screening (3 contact hours); Active learning- Colorectal Cancer

PHA5787 Patient Care V Endocrinology and Women's & Men's Health

2019-2021: Lecturer- Breast Cancer, Ovarian Cancer, Prostate Cancer (4 contact hours); Active learning - Breast Cancer, ovarian cancer, prostate cancer

PHA5876 Patient Care VIII Complex Patients

2018-2021: Lecturer - Oncologic emergencies/Neutropenic Fever (4 contact hours); Active learning – oncologic emergencies, neutropenic fever

PHA5789 APPE Readiness

2019-2021 Case Discussion Facilitator

### ***Ph.D. Curriculum***

PHA6449 Pharmacogenomics

2018: Lecturer- Epigenetics and Pharmacogenomics – DNA Methylation (1 contact hour)

### ***Experiential Experiences***

<b>Year</b>	<b>Rotation</b>	<b>Practice Site</b>	<b>Trainees</b>
2019 – current	Clinical Research 101 (Elective)	Med Plaza- Clinical Trials	6 hematology/oncology fellows/year

### **University of Georgia College of Pharmacy**

#### ***Pharm.D. Curriculum***

PHRM 3800: Clinical Applications

2006-2007: Course coordinator, patient-based learning (8 contact hours)

PHRM 5210: Clinical Oncology Elective

2007-2008: Course coordinator, Interactive cases, experiential component (12 contact hours)

PHRM 5870: Pharmacotherapy II

2007-2017: Course coordinator (2017), Lecturer, interactive cases, TBL (6 contact hours/year); lecturer - Breast cancer (1 semester), Bone marrow transplantation (3 semesters), Growth factors (1 semester)

CINV (6 semesters, co-mentored PGY2 resident), Systemic fungal infections (5 semesters), Oncologic emergencies (2 semesters)

PHRM 5140: Clinical Skills Lab

2007-2008: Co-course coordinator, facilitated OSCEs (12 contact hours)

PHRM 4190: Cancer and Chemotherapy

2009-2012: Co-course coordinator (10-12 contact hours/year)

PHRM 5210: Landmark Clinical Studies in Oncology and Clinical Applications Elective

2010 -2011: Course coordinator, Seminars, interactive cases, experiential

PHRM 5920: Clinical Seminar

2011-2017: Student semester mentoring (3-5 contact hours/semester)

PHRM 5190: Anticancer therapeutics

2013-2015: Lecturer (5-10 contact hours/semester)

PHRM 5210: Insights into Clinical Practice

2015: Small group interactive cases (2 contact hours)

PHRM 5210: Resident Rounds

2015: Course coordinator, Small group cases, didactic lectures (12 contact hours)

PHRM 3520: Interpreting Clinical Lab Tests

2016-2017: Lecturer - Hematology: Red and White Blood Cells (1contact hour)

PHRM 3030: Essentials of Pharmacy Practice I

2016: Small-group recitation (8 contact hours)

PHRM 3040: Essentials of Pharmacy Practice I

2017: Small-group recitation (8 contact hours)

PHRM 4040: Essentials of Pharmacy Practice IV

2017: Skills lab coordinator – Handling hazardous agents (4 contact hours)

PHRM 5210: Integrated Patient Cases

2017: Cases and Simulated EMR (2 contact hours)

### ***Experiential Experiences***

Year	Rotations	Practice Site (s)	Students- hours
------	-----------	-------------------	-----------------



2007- 2017	5901-5908 (APPE)	<ul style="list-style-type: none"> <li>• Inpatient Hematology/Oncology</li> <li>• BMT</li> <li>• Outpatient Oncology</li> </ul>	8-10 students per year  150- 200 contact hours per rotation
2012- 2017	IPPE	<ul style="list-style-type: none"> <li>• Oncology</li> </ul>	8-12 students per year

### ***Resident Graduate Curriculum***

<b>Year</b>	<b>Rotations</b>	<b>Format</b>	<b>Graduate students-hours</b>
2011-2017	PHRM 7210 Advanced Pharmacy Care	Small group discussion	5-7 students- 5 contact hours/year
2011-2017 (Fall semesters)	PHRM 7810 Pharmacy Care	Direct precepting	1-2 students- > 100 contact hours
2011-2017	PHRM 7910 Adv Pharmacy Care	Direct precepting	>100 contact hours
2011- 2017	PHRM 7830 Residency Research	Research advising	1-2 students- > 100 contact hours
2011- 2017	PHRM 7840 Teaching Pharmacy Practice	Advising	1 students -> 10 contact hours
2011- 2017	PHRM 7940 Teaching Pharmacy Practice PGY2	Advising	1-2 students -> 10 contact hours
2012-2013	PHRM 7210 Special Topics PGY2 Oncology Residents	Interactive cases	10 contact hours

### **Medical College of Georgia College of Allied Health- Physician Assistant Program**

2009-2015                      *Chemotherapy 101*  
    *Chemotherapy Induced Nausea-Vomiting*  
    Format: Didactic lectures

### **Medical College of Georgia College of Nursing**

2008-2012                      NSG 7430 - Pharmacology for Advanced Practice Nurses  
    *Pain Management* (3 contact hours annually)  
    *Adjuvant Treatments in Cancer* (3 contact hours annually)

### **University of Kentucky College of Pharmacy**

Spring 2004                      Integrated Applied Therapeutics II (PHR 963)  
    (2 contact hours)

Fall 2004	Integrated Applied Therapeutics I (PHR 962) (2 contact hours)
Fall 2003	Contemporary Aspects of Pharmacy Practice (PHR 939) (8 contact hours)
Spring 2002	Contemporary Aspects of Pharmacy Practice (PHR 919) (8 contact hours)

**University of Kentucky College of Allied Health Sciences-Physician Assistant**

Spring 2003	Pharmacology Course <i>Immunomodulating Agents</i> <i>Antineoplastic Agents</i> (2 contact hours)
-------------	--

**POSTGRADUATE TRAINEES**

**UGA –Augusta University PGY2 Oncology Pharmacy Residency Program Director**

<b>Year</b>	<b>Graduate Resident</b>	<b>First Clinical Position</b>
2011-2012	Katerina Katsanevas Butler, Pharm.D BCOP	Oncology Clinical Specialist VA Medical Center Salt Lake City, UT
2012-2013	Stephen Clark, Pharm.D. BCOP	BMT Clinical Specialist University of North Carolina Chapel Hill, NC
2012-2013	Alison Steinbach, Pharm.D	Outpatient Clinical Specialist West Penn Allegheny Hospital Pittsburgh, PA
2013-2014	Megan Hartranft, Pharm.D. BCPS, BCOP	Clinical Assistant Professor Rosalind Franklin College of Pharmacy Rush Cancer Center Chicago, IL
2014-2015	Sarah Evans, Pharm.D. BCOP	Outpatient Clinical Specialist The Ohio State Medical Center James Cancer Center Columbus, OH
2015- 2016	Julianne Orr, Pharm.D. BCOP	Outpatient Clinical Specialist Indiana Health Indianapolis, IN
2016-2017	Ben Andrick, Pharm.D. BCOP	BMT Clinical Specialist Geisinger Health System Danville, PA

7/2017-8/2017	Morgan Gwynn, Pharm.D. BCOP	Melanoma & Thoracic Clinical Specialist UNC Medical Center Chapel Hill, NC
---------------	-----------------------------	--

#### UGA Clinical and Experimental Therapeutics (CET) Clinical Program Training

Year	Graduate Student	Rotation
2010	Belal Al-Husein, M.S.	Inpatient Oncology
2012	Ahmed Al-Azayzih, Pharm.D. BCOP	Inpatient Oncology
2014	Harika Sabbineni, B.Pharm.	Outpatient BMT

#### UGA Clinical and Experimental Therapeutics Ph.D. Dissertation Committee Member

Year	Graduate Student	Thesis Title
2010-2011	Belal Al-Husein, M.S.	Molecular mechanisms regulating simvastatin-mediated inhibition of prostate cancer cellular functions <i>in vitro</i> and tumor growth <i>in vivo</i>
2011-2012	Ahmed Al-Azayzih, Pharm.D. BCOP	Role of Akt in myofibroblast differentiation leading to pulmonary vascular remodeling and idiopathic pulmonary fibrosis

#### UF Pharmacotherapy and Translational Research Ph.D. Dissertation Committee Member

Year	Graduate Student	Thesis Title
2021-present	Nam Nguyen, Pharm.D. M.S.	CRISPR/Cas9 Synthetic Lethal Screens to Identify Genomic Resistant/Sensitive Drivers of Ara-C, Daunorubicin, Etoposide (ADE) Treatment in AML

#### PGY1/PGY2 Pharmacy Residency Precepting

Year	Graduate Resident	Rotation
2020-2021	Tia McCormick, Pharm.D.	Clinical Research (mini-block)
2019-2020	Kaitlyn Kowalski, Pharm.D.	Academic

2019-2020	Kaitlyn Kowalski, Pharm.D.	Administration – Longitudinal
2010-2011	Katerina Katsanevas, Pharm.D BCOP	Inpatient hematology/oncology
2009-2010	Karly O'Brien, Pharm.D.	Inpatient hematology/oncology
2009-2010	Ashley Richard, Pharm.D.	Inpatient hematology/oncology
2009-2010	Amber Bradley, Pharm.D. BCOP	Inpatient hematology/oncology
2008-2009	Neha Dosi, Pharm.D.	Inpatient hematology/oncology
2008-2009	Evelina Maciuleviciute, Pharm.D.	Inpatient hematology/oncology
2007-2008	Tim Robinson, Pharm.D. BCPS	Inpatient hematology/oncology
2007-2008	Kinjal Vikal, Pharm.D.	Inpatient hematology/oncology

## **GRANTS**

1. *Analysis of febrile neutropenia in multiple myeloma patients post-autologous hematopoietic stem cell transplantation.* University of Georgia Randy Ellison Cancer Research Grant. Project period 10/06-5/07. (Primary Investigator, 50% effort). Total award \$2000
2. *Is GSK-3 the gridlock in Akt-targeted prostate cancer therapy?* University of Georgia Translational Research Initiative Grant. Project period 10/11-07/12. (Sub-Investigator, 5% effort). Total award \$7500
3. *Evaluation of cabazitaxel and dasatinib on the reciprocity between prostate cancer and the endothelium in the prevention of micrometastasis.* Submitted 9/12 for University of Georgia Translational Research Initiative Grant. Project period 10/12-07/13. (PI, 5% effort). Total award \$10,000
4. *Examining TGF $\beta$  and Integrin  $\alpha$ v $\beta$ 3 Expression in Early and Aggressive Human Prostate and Bladder Cancer Tissues as Biomarkers for early detection and as targets for therapy.* Project period 2013-14. University of Georgia Translational Research Initiative Grant. (Sub-investigator, 5% effort). Total award \$10,000
5. *Evaluation of the effects of obesity on the epigenome in acute myeloid leukemia patients: Correlation with clinical outcome and drug response.* University of Georgia College of Pharmacy R.C. Wilson Fund. Project period 2014-2015. (PI, 75% effort). Total award \$4,500
6. *Pneumococcal vaccine response in chronic lymphocytic leukemia (CLL) patients receiving ibrutinib.* University of Georgia College of Pharmacy R.C. Wilson Fund. Project period 2015-2016. (PI, 75% effort). Total award \$4,000

**OTHER SCHOLARLY/CREATIVE WORKS**

1. In collaboration, designed – Required Competency Areas, Goals, and Objectives for PGY2 Oncology Pharmacy Residencies (2017) - <http://www.ashp.org/DocLibrary/Residents/Oncology-Pharmacy-2016.pdf>

**HONORS AND AWARDS**

2020	UF College of Pharmacy Teaching Service Award
2019	Elected to Fellowship in HOPA
2015	Elected to Fellowship in ACCP
2014	ACCP Annual Meeting – Best Paper Award
2014	ACCP Hematology/Oncology PRN FIT Program Scholarship Recipient
2012	Georgia Society of Health-System Pharmacists (GHSP) Outstanding Practitioner of the Year
2005	ACCP Research Travel Award
2003	Clinical Pharmacy Residents Program Educational Grant- Pfizer
2003	University of Kentucky Medical Center Resident of the Month
1996	Howard Hughes Research Institute Research Award

**ADMINISTRATIVE ACTIVITY/COMMITTEES**University of Florida Health College of Pharmacy

2018-present	Member, Admissions Committee
2018-2020	Member, Promotion and Tenure Committee
2019-2020	Chair, AACP Self-Study Committee (Standards 14-17)
2018-2019	Member, Search Committee Ass Dean Education
2018	Chair, Search Committee Clinical Assistant Professor (Pharmacogenomics)

University of Florida Health Cancer Center

2017-present	Member, Scientific Review and Monitoring Committee (SRMC)
2017-2019	Member, Cancer Therapeutics and Host Response Committee
2017-2018	Member, Data Integrity and Safety Committee (DISC)
2017-2019	Member, Translational Research Accelerator Committee

University of Florida

2019 – 2020	Mentor, University Multicultural Mentor Program (UMMP)
-------------	--

University of Georgia College of Pharmacy

2016-2017	Academic and Professionalism Committee
2013-2017	Student Wellness Committee
2013-2017	Students Oncological Advocates in Pharmacy (SOAP)- Faculty Advisor
2014-2016	Academic House Host – Augusta PGY3 students
2014-2016	Chair, Clinical Tracks Work Group
2010- 2012	UGA Faculty alternative delegate for American Association of Colleges of Pharmacy (AACP)
2009-2013	Member, Scholarship and Awards Committee 2012-2013 Chair
2007-2009	Member, Faculty Development Committee
2006-2009	Admissions Committee

Augusta University (formerly known as -Georgia Regents University (GRU))

2012-2017	Member, Cancer Institutional Review Board (C-IRB)
2012-2017	Associate Member GRU Cancer Center
2008-2017	GRU/UGA Pharmacy Residency Advisory Committee (RAC) member
2006-2017	GRU BMT/Hematologic Malignancies Committee
2005-2017	GRU Oncology Pharmacy and Therapeutics Subcommittee
2005-2006	Medical College of Georgia Palliative Care Committee

University of Kentucky

2003-2005	UK Oncology Pharmacy and Therapeutics Subcommittee
2003-2004	UK Medical Center Medication Use Evaluation Subcommittee
2002-2003	UK College of Pharmacy Admissions Committee (Resident member)

**PROFESSIONAL ACTIVITY AND SERVICE**Membership – Professional Organizations

2018-present	American Pharmacists Association (APhA)
2017 -present	American Society of Clinical Oncology (ASCO)
2012-2014	American Society for Blood and Marrow Transplantation (ASBMT)
2005- present	Hematology/Oncology Pharmacy Association (HOPA)
2006-2019	Georgia Health Systems Pharmacy (GSHP)
2002-2005	Kentucky Health System Pharmacists (KSHP) member
2002- present	American College of Clinical Pharmacy (ACCP)
2001-2012	American Society of Health System Pharmacists (ASHP)
1998-2002	Kappa Psi Pharmaceutical Fraternity

Service – Professional Organizations

2020-present	NRG Oncology Pharmacy Subcommittee
2019 – present	American Pharmacists Association (APhA) House of Delegates (HOPA representative)
2015-2018	National Community Oncology Dispensing Association (NCODA) <ul style="list-style-type: none"> <li>○ Executive Advisory Board (2016-2017)</li> <li>○ Advisory Board (2017-2018)</li> </ul>
2006-present	Hematology/Oncology Pharmacy Association (HOPA) member <ul style="list-style-type: none"> <li>○ Past-President, Board of Directors (2021-current) <ul style="list-style-type: none"> <li>▪ Public Policy Committee</li> <li>▪ Professional Development Council Chair</li> </ul> </li> <li>○ President, Board of Directors (2020-2021) <ul style="list-style-type: none"> <li>▪ Public Policy Committee</li> <li>▪ Finance Committee</li> <li>▪ IRC Committee</li> <li>▪ Leadership Development Subcommittee</li> </ul> </li> <li>○ President-Elect, Board of Directors (2019-2020) <ul style="list-style-type: none"> <li>▪ Public Policy Committee</li> <li>▪ Advocacy Council</li> <li>▪ Finance Committee</li> </ul> </li> <li>○ Oncology Pharmacy Competency and Certificate Program Task Force (2018- 2020)</li> <li>○ Vice-Chair, Tools and Resources Committee (2017-2019)</li> <li>○ Oral Chemotherapy Education Task Force (2016-present)</li> <li>○ Board of Directors, Member at Large (2015- 2017)</li> </ul>

- Advocacy HOPA On the Hill Day Washington, DC 2015, 2016, 2017, 2019
- Committee Restructuring Task Force (2016)
- Board Liaison, Practice Management (2016-2017)
- Board Liaison, Annual Program Committee (2016-2017)
- Board Liaison, Membership Committee (2015-2016)
- Board Liaison, Publications Committee (2015- 2016)
- BIG idea Taskforce (2015-2016)
- Vice Chair, Recognition Committee, (2014- 2015)
- Research and Abstract Review Committee (2010-2013)
- Poster Reviewer (2009-2012)

2002-present

American College of Clinical Pharmacy (ACCP)

- Research Committee, member (2015-2016)
- Hematology/Oncology PRN Chair (2015-2016)
- Hematology/Oncology PRN Chair Elect (2014-2015)
- Hematology/Oncology PRN program committee (2014-2016)
- Academy Resident Mentor participant (2013- current)
  - Mentee – Julianne Orr, Pharm.D. (PGY1 Resident, Greenville Health System)
  - Mentee- Sarah Hayes, Pharm.D. (PGY1 Resident, N. Memorial Medical Center)
  - Mentee- Deeter Neuman, Pharm.D. (PGY1 Resident, University of Michigan)
  - Mentee – Manuel Cortez, Pharm.D. (PGY2 Oncology Resident, University of Chicago)
  - Mentee – Aaron Stewart, Pharm.D. (PGY1 Resident, VA Sierra Nevada Health Care)
  - Mentee- Shahrier Hossain, Pharm.D. (PGY1 Resident, Albany Medical Center)
- Student CV Reviewer (2012- current)
- Student Trivia Game Writer – Oncology (2010-2011) and (2016-2017)
- Hematology/Oncology PRN Member (2003- current)

**CONSULTING**

2013-2016

Merck – Speakers bureau

2010-2012

Georgia Department of Public Health - Georgia Cancer State Aid Program Formulary Reviewer



**SCIENTIFIC JOURNAL REFEREE AND BOOK REVIEWER**

Books

2013 Reviewer, Pharmacotherapy Principles and Practice -3<sup>rd</sup> edition  
Chapter- *Malignant Lymphomas*

Journals

2020 – present *Pharmacy*  
2019 –present *Clinical Lymphoma, Myeloma, and Leukemia*  
2019-present *Journal of American College of Clinical Pharmacy (JACCP)*  
2017-present *Supportive Care in Cancer*  
2017-present *Journal of Pharmacy Technology*  
2016-present *BMJ Open*  
2014-present *Journal of Hematology/Oncology Pharmacy*  
2013-present *Annals of Pharmacotherapy*  
2013-present *Pharmacotherapy*  
2012-present *American Journal of Health Systems Pharmacists*

**EDITORIAL ACTIVITY**

2019 – present Editorial board member, *Journal of American College of Clinical Pharmacy (JACCP)*

2014- 2016 Essential Oncology/McMahon Publishing – Computer Apps for Oncology Professionals

**COMMUNITY SERVICE**

2013-2017 Upward Sports Coach (Soccer, Basketball)  
2009-2017 Leukemia and Lymphoma Society – Light the Night fundraising GRU team member  
2003-2005 Life Adventure Camp  
1998-2002 Faith Pharmacy Volunteer  
1992-1996 King of the Bluegrass Flag Football Tournament for Big Brothers/Big Sisters